Roche ends cancer deal with Oryzon

Oryzon Genomics S.A. (Madrid:ORY) fell €0.80 (27%) to €2.11 on Thursday after Roche (SIX:ROG;OTCQX:RHHBY) terminated a 2014 deal granting the pharma rights to cancer candidate ORY-1001. Oryzon said Roche's decision was part of a portfolio reprioritization.

Roche is responsible for completing an ongoing Phase I trial evaluating the inhibitor of lysine-specific demethylase 1 (KDM1A; LSD1) to treat small cell lung cancer (SCLC). The compound has completed a Phase I/IIa trial to treat acute myelogenous leukemia (AML)...